Search Results

You are looking at 61 - 70 of 1,499 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

HSR23-106: Real-World Study of Disease-Free Survival and Associated Patient Characteristics in Early-Stage Non–Small Cell Lung Cancer (NSCLC): A Retrospective Observational Study

Anne Shah, Jon Apple, Andrew J. Belli, Anna Barcellos, Eric Hansen, Laura L. Fernandes, and Ching-Kun Wang

(rwDFS) and patient characteristics, including epidermal growth factor receptor mutation (EGFRm) status, associated with rwDFS in stages IB-IIIA NSCLC patients. Methods: This was a retrospective cohort study using COTA’s real-world US oncology database

Full access

Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014–2017

Mohammed W. Rahman, Niti U. Trivedi, Peter B. Bach, and Aaron P. Mitchell

relatively similar proportions of physicians who had graduated <11 years, 11 to 20 years, 21 to 30 years, or >30 years before the study period. Table 1. Physician Characteristics The proportion of oncologists who received any payments within the

Full access

HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases

Naleen Raj Bhandari, Neha Bansal, Chi-Wei Duann, Anasofia Afonso, and Shen Zheng

Background: Since the approval of selpercatinib in 2020, limited real-world studies on its use in rearranged during transfection (RET)-altered tumors exist. This study described baseline sociodemographic, clinical, and treatment characteristics

Full access

A Hospital-Wide Intervention to Improve Compliance With TNM Cancer Staging Documentation

Jason H. Lee, Tariq Mohamed, Celia Ramsey, Jihoon Kim, Shelly Kane, Kathryn A. Gold, Farhoud Faraji, and Joseph A. Califano III

association of patient, provider, and treatment team characteristics, including 1- or 2-month deadline, with the prevalence of and time to staging. Patient characteristics included age, sex, race, and Charlson comorbidity index (CCI) score. Provider

Full access

HSR20-111: Characteristics, Treatment Patterns, Healthcare Resource Use and Costs among Pediatric Patients Diagnosed with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Retrospective Database Analysis

Xiaoqin Yang, Kaushal Desai, Neha Agrawal, Kirti Mirchandani, Sagnik Chatterjee, Eric Sarpong, and Shuvayu Sen

describe the characteristics, treatment patterns, healthcare resource use (HRU) and costs for these patients. ​ Methods: A retrospective study of individuals enrolled in the MarketScan ® Commercial Claims and Encounters claims database from 10

Full access

HSR20-097: Granulocyte Stimulating Colony Factor Use, Characteristics and Treatment Patterns in the United States: An Updated Analysis by the Biologics and Biosimilars Collective Intelligence Consortium

Catherine Lockhart, Cara McDermott, James Marshall, Aaron Mendelsohn, Pamala Pawloski, and Jeffrey Brown

. Objective: To evaluate patient characteristics and treatment use patterns in patients treated with GCSFs. This analysis will help inform a large-scale, real-world, observational GCSF comparative effectiveness research (CER) study using the Biologics

Full access

Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer

Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Megan E. Miller, Artur H. Sousa-Santos, Amanda L. Amin, and Alberto J. Montero

therapies, such as chemotherapy, endocrine therapy, trastuzumab, and bisphosphonates, on OS in patients with breast cancer. 4 , 5 Provided with basic inputs of an individual patient’s clinicopathologic characteristics, PREDICT provides personalized

Full access

HSR20-089: Association of Patient Clinico-Genomic Characteristics With Tumor Mutational Burden in Small Cell Lung Cancer: An Observational Study

Sumesh Kachroo, Changxia Shao, Kaushal Desai, Jinghua He, Fan Jin, and Shuvayu Sen

Background: This study evaluated the relationship between patients’ clinical and genomic characteristics and high tumor mutational burden (TMB) in the context of small cell lung cancer (SCLC). Methods: This was a retrospective cohort study using

Full access

EPR23-083: Non-Squamous, Metastatic Non–Small Cell Lung Cancer: Retrospective c-Met Overexpression Testing, Patient Characteristics, and Treatment Patterns

Mona H. Cai, Yookyung Christy Choi, Athan Vasilopoulos, Alexander Liede, Sidney S. Lindsey, Leon Raskin, Ethan Truong, Jeremy Fricke, Stephen B. Gruber, and Peter J. Ansell

-Met OE negative (NEG) were less likely to be Asian (14% vs 30%, respectively), more likely to be diagnosed with stage IV disease (57% vs 41%), and more likely to be PD-L1 POS (78% vs 41%). All other observed characteristics were similar between groups

Full access

Impact of NCI-Mandated Scientific Review on Protocol Development and Content

Ning Ning, Jingsheng Yan, Xian-Jin Xie, and David E. Gerber

following characteristics: year, disease under study, phase and type (interventional/noninterventional), and sponsor type (institutional/industrial). Institutional trials included investigator-initiated trials with a local study chair or a study chair at